Search company, investor...

Founded Year

2010

Stage

IPO | IPO

Total Raised

$140.51M

Date of IPO

9/25/2023

About YZY Biopharma

YZY Biopharma (02496.HK) develops bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and geriatric ophthalmology to solve oncology and geriatric ophthalmology problems. It helps to solve medical needs in these fields of diseases by using biotechnology to develop drugs and vaccines. The company was founded in 2010 and is based in Wuhan, China.

Headquarters Location

No. 666 Gaoxin Avenue, East Lake New Technology Development Zone Building C2-1, Optics Valley Biocity

Wuhan, Hubei,

China

027-82668988

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Latest YZY Biopharma News

Wuhan YZY raises $15 million in Hong Kong IPO to advance BsAbs

Sep 26, 2023

Sep. 26, 2023 Wuhan YZY Biopharma Co. Ltd. made its debut on the Hong Kong Stock Exchange, raising HK$121 million (US$15.48 million) in its IPO on Sept. 22, with shares (HKEX:02496) opening at the lower end of its range at HK$16 per share and ending the day at HK$16.60, a rise of 3.75%.

YZY Biopharma Frequently Asked Questions (FAQ)

  • When was YZY Biopharma founded?

    YZY Biopharma was founded in 2010.

  • Where is YZY Biopharma's headquarters?

    YZY Biopharma's headquarters is located at No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan.

  • What is YZY Biopharma's latest funding round?

    YZY Biopharma's latest funding round is IPO.

  • How much did YZY Biopharma raise?

    YZY Biopharma raised a total of $140.51M.

  • Who are the investors of YZY Biopharma?

    Investors of YZY Biopharma include Optics Valley Financial Holding Group, Wuhan Hi-Tech, Hubei Science & Technology Investment Group, TD Capital, Camel Fund and 12 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.